Evolent Health, Inc. Q2 FY2025 earnings call

• Organic growth: Four new revenue agreements year-to-date across Technology, Services, and Performance Suite, totaling 11 new agreements. Three new agreements in Tech and Services, and expansion in the Performance Suite with Aetna in Florida for 250,000 Medicare Advantage members.
• Margin expansion: Focus on Performance Suite margin maturation and AI/automation. Oncology expenses were below forecast, AI integration improved review efficiency by ~11%, targeting 80% auto approval of authorization volume.
• Capital allocation: Priorities include organic product development, deleveraging, and no near-term M&A.

In Q2, adjusted EBITDA was $37.5 million. Q2 revenue was $444 million, $11 million below the midpoint of the guide. The Performance Suite saw a normalized oncology trend of approximately 10.5%, modestly below the initial forecast of 12%. On the top line, the deviation was due to 2024 revenue updates and go-live timing issues for the Performance Suite. Adjusting for a Q1 contract, Q2 had a $16 million sequential step-up. Revenue contribution details: Technology, Services, and Performance Suite segments contributed to the overall revenue, with new agreements driving organic growth.

• Adjusted EBITDA outlook: $140 million to $165 million for 2025, with Q3 adjusted EBITDA between $34 million and $42 million.
• Revenue outlook: $1.85 billion to $1.88 billion for 2025, with Q2 revenue between $460 million and $480 million, impacted by Aetna go-live timing.

• Macro environment challenges for managed care, including elevated utilization, lagging premiums. Uncertainty in Medicaid policy implementation and potential headwinds in ACA exchange membership.

Q: Jared Haase at William Blair asked about Aetna announcement, density, and margin profile ramp.

A: Seth Blackley talked about partnering with Aetna, Florida as a starting point, and margin ramp to target 10% over two years.

Q: Kevin Caliendo at UBS asked about new contracts and how conversations are different.

A: Seth Blackley mentioned a $1 billion weighted pipeline, enhanced contracts with protections.

Q: Daniel Grosslight at Citi asked about Aetna contract push to Q1 2026.

A: Seth Blackley said disciplined about partnership components and data exchange honing.

Q: John Paul Stansel at JPMorgan asked about exchanges in '26.

A: John Paul Johnson mentioned 20% revenue from exchanges, assumptions on morbidity, and focusing on downside protection.

Q: Eduardo Ron at Truist asked about $2.5B 2026 target and incremental revenue.

A: John Paul Johnson said based on weighted pipeline, Seth Blackley added pipeline over $1 billion.

Q: Charles Rhyee at TD Cowen asked about exchanges impact and customer discussions.

A: John Paul Johnson assumed exchange population decline, Seth Blackley talked about Performance Suite value proposition.

Q: Matthew Glimmer at KeyBanc asked about oncology trend and exchange utilization pull forward.

A: John Paul Johnson said 10.5% trend, conservative guide for second half, and exchange pull forward.

Q: Jenny Shen at BTIG asked about MSK and new customers.

A: John Paul Johnson said focused on building 2026.

Q: David Larsen at BTIG asked about utilization in other specialties.

A: John Paul Johnson said cardiology trend consistent.